Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617981 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Imunon.
- Completed
- Registry status
- Phase 3
- Development phase
- 701
- Enrollment target
- 20
- Study locations
NCT00617981: Completed Phase 3 study of Hepatocellular Carcinoma, sponsored by Imunon.
NCT00617981 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Imunon. The registered enrollment target is 701 participants, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (177% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617981, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Imunon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 701 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency ablation (RFA).
Conditions Studied
Interventions
- DRUG ThermoDox
- DRUG 5% Dextrose Solution
Study Locations (20)
Pennsylvania
- Temple University Hospital - Philadelphia
- Geisinger Health System - Wilkes-Barre
Jiangsu
- Nanjing Drum Tower Hospital, The Affilitated Hospital of Nanjing University Medical School - Nanjing
- The First Affiliated Hospital of Suzhou University - Suzhou
Other
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital, Peking University School of Oncology - Beijing
California
- UCLA - Los Angeles
Florida
- Mayo Clinic - Jacksonville, Florida - Jacksonville
Kentucky
- University Of Louisville - Louisville
Minnesota
- Mayo Clinic - Rochester
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2008-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
What the finished NCT00617981 record still lists
NCT00617981 is an interventional study that assigns participants to a tested intervention. The registered 701 participants enrollment target is mid-sized for trials with a published cap, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (177% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which ThermoDox is the first listed.
NCT00617981 names 20 study sites across 17 states, led by Pennsylvania, Jiangsu, Other.
Frequently Asked Questions
What is clinical trial NCT00617981 about?
NCT00617981 is a clinical study titled "Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)". The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency ablation (RFA).
What is the current status of trial NCT00617981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 701 participants. The study started on 2008-05. Estimated completion is 2016-08.
What conditions does trial NCT00617981 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00617981?
The interventions under investigation include: ThermoDox (DRUG), 5% Dextrose Solution (DRUG).
Who is sponsoring clinical trial NCT00617981?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00617981 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00617981's enrollment target sits among peer trials
701 19th of 145 higher than 127 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia